Assignment history

Inventors

Based on the patent documentation, the sole inventor is Michael Ragusa. At the time of the application filing on May 30, 2017, the original assignee was Haemonetics Corporation, indicating that Michael Ragusa was likely employed by or had an obligation to assign inventions to Haemonetics Corporation.

Original assignee

The original assignee of US patent 10,758,652 is Haemonetics Corporation. Haemonetics is a global healthcare company that provides a suite of medical products and services for blood and plasma collection, processing, and transfusion. The company's products, including apheresis systems for plasma collection, appear to embody the claims of the patent, which details a "System and method for collecting plasma." Haemonetics Corporation is an active, publicly traded operating company (NYSE: HAE).

Assignment timeline

A search of the USPTO Patent Assignment Search database for US Patent 10,758,652 reveals a single assignment recorded.

• 2018-05-01 (executed) / recorded 2018-05-22 — Reel 044100/0358
  • Conveyance: Assignment of Assignor's Interest
  • Assignor: RAGUSA, MICHAEL
  • Assignee: HAEMONETICS CORPORATION
  • Correspondent: Matthew F. Lambrinos, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210
  • Context: This is the initial assignment from the inventor to the original assignee, Haemonetics Corporation, formalizing the company's ownership of the invention.

No other assignments have been recorded for this patent as of 2026-05-13. The patent remains with the original assignee.

Timeline diagram

timeline
    title Ownership of US 10758652
    2017 : Application filed
         : Inventor Michael Ragusa assigns to Haemonetics Corp
    2020 : Patent issued

NPE / troll-pattern signals

1. Shell-entity transfer: Not present. The patent has not been transferred from the original operating company assignee.

2. Known asserter in the chain: Not present. The sole assignee, Haemonetics Corporation, is a product company, not a listed NPE.

3. Repeat correspondent across the chain: Not present. There is only one recorded assignment.

4. Cascading transfers: Not present. There are no subsequent transfers.

5. Pre-litigation transfer: Not present. The patent has not been assigned post-issuance. According to information on the Google Patents page for US10758652, there is pending litigation, but no pre-litigation transfer is recorded.

6. Bankruptcy fire-sale: Not present. Haemonetics Corporation is a financially active company.

7. Privateering: Not present. The patent has not been transferred to a third-party assertion entity.

8. Defensive aggregator (anti-NPE): Not present. The patent is held by its original operating company assignee.

Verdict

Insufficient data

The USPTO assignment records show only the initial inventor-to-assignee transfer to Haemonetics Corporation (Reel 044100/0358). There is no recorded evidence of any transfer to a non-practicing entity or other assertion-focused vehicle. The patent remains with the original operating company that develops and sells products in the field of the invention. While litigation is noted, without a transfer of ownership, it falls outside the typical NPE pattern.

A direct search can be verified at the USPTO Patent Assignment Search by entering patent number 10758652.